BDNF Val66Met polymorphism and peripheral protein levels in pediatric bipolar disorder and attention‐deficit/hyperactivity disorder Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • ObjectiveFrontiers between pediatric bipolar disorder (PBD) and attention‐deficit/hyperactivity disorder (ADHD) are not well defined. Few studies have addressed potentially different neurobiological factors between the two disorders. Brain‐derived neurotrophic factor (BDNF) has been increasingly recognized for its etiologic and prognostic role in adult bipolar disorder (BD) studies. This study aimed to examine the BDNF gene polymorphism and potential alterations in BDNF serum levels in the pediatric ADHD patients with or without comorbid BD illness.MethodWe assessed the non‐synonymous single‐nucleotide polymorphism in the BDNF gene (rs6265/Val66Met) and its serum levels in children and adolescents with BD comorbid with ADHD (BD + ADHD) and ADHD alone. Children and adolescents were assessed for psychiatric diagnoses using the Kiddie‐Sads‐Present and Lifetime Version (K‐SADS‐PL).ResultsUsing Analysis of covariance (ancova) we detected a significant group effect (patients with BD + ADHD had higher serum levels than those with ADHD – F80,3 = 8.73, P = 0.005).ConclusionAlthough the Val66Met polymorphism at the BDNF gene does not seem to play a significant role in children and adolescents with BD or ADHD, BDNF serum levels deserve further attention in future research on neurobiological aspects of BD and ADHD.


  • Zeni, CP
  • Tramontina, S
  • Aguiar, BW
  • Salatino‐Oliveira, A
  • Pheula, GF
  • Sharma, A
  • Stertz, L
  • Moreira Maia, CR
  • Hutz, M
  • Kapczinski, Flavio
  • Rohde, LA

publication date

  • September 2016